CHMP gives positive opinion for etanercept biosimilar (Nepexto)

Market authorisation is recommended for this biosimilar for the indications as per the reference product (Enbrel) – i.e. rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis plaque psoriasis and paediatric plaque psoriasis.

European Medicines Agency